Clinical Trials
58 trialsHighly Conformal, Hypofractionated, Focally Dose Escalated Post-Prostatectomy Radiotherapy
National Institutes of Health Clinical Center (CC)
Testing the Safety of the Anti-cancer Drug, Sn-117m-DTPA, for Advanced Cancers That Have Spread to Bones
National Cancer Institute (NCI)
PI3Kbeta Inhibitor AZD8186 and Docetaxel in Treating Patients Advanced Solid Tumors With PTEN or PIK3CB Mutations That Are Metastatic or Cannot Be Removed by Surgery
National Cancer Institute (NCI)
Akt Inhibitor MK2206 and Hydroxychloroquine in Treating Patients With Advanced Solid Tumors, Melanoma, Prostate or Kidney Cancer
National Cancer Institute (NCI)
Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV
National Cancer Institute (NCI)
Prostate SBRT for Locally Recurrent Prostate Cancer After Prior Radiotherapy
National Institutes of Health Clinical Center (CC)
The Effects of Castration on the Pharmacokinetics of Zolpidem After Single Dose Administration In Men With Prostate Cancer Undergoing Androgen Deprivation Therapy Compared to Normal Healthy Females
National Institutes of Health Clinical Center (CC)
Romidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver Dysfunction
National Cancer Institute (NCI)
Testing the Addition of Immunotherapy With Hu5F9-G4 (Magrolimab) to the Usual PARP Inhibitor, Olaparib for Treatment of Metastatic or Recurrent Breast or Castrate-Resistant Prostate Cancer With BRCA Mutations
National Cancer Institute (NCI)
A Pilot Study of Vaccination With Epitope-Enhanced TARP Peptide and TARP Peptide-Pulsed Dendritic Cells in the Treatment of Stage D0 Prostate Cancer
National Institutes of Health Clinical Center (CC)
Treatment of Castration Resistant Prostate Cancer Using Multi-Targeted Recombinant Ad5 PSA/MUC1/Brachyury Based Immunotherapy Vaccines
National Institutes of Health Clinical Center (CC)
Study to Compare Capsule and Liquid Formulations of Enzalutamide After Single Dose Administration Under Fasting Conditions in Prostate Cancer
National Institutes of Health Clinical Center (CC)
Safety and Tolerability of a Modified Vaccinia Ankara (MVA)-Based Vaccine Modified to Express Brachyury and T-cell Costimulatory Molecules (MVA-Brachyury-TRICOM)
National Institutes of Health Clinical Center (CC)
Multi-Targeted Recombinant Ad5 (CEA/MUC1/Brachyury) Based Immunotherapy Vaccine Regimen in People With Advanced Cancer
National Institutes of Health Clinical Center (CC)
Ipilimumab and Sargramostim in Treating Patients With Metastatic Prostate Cancer
National Cancer Institute (NCI)
Vaccine and Antibody Treatment of Prostate Cancer
National Institutes of Health Clinical Center (CC)
An Open Label Phase I Study to Eval the Safety and Tolerability of a Vaccine (GI-6207) Consisting of Whole, Heat-killed Recombinant Saccharomyces Cerevisiae (Yeast) Genetically Modified to Express CEA Protein in Adults With Metastatic CEA-expressing ...
National Institutes of Health Clinical Center (CC)
Ketoconazole Plus Docetaxel to Treat Prostate Cancer
National Institutes of Health Clinical Center (CC)
Phase I Study of Intensity Modulated Radiation Therapy for Prostate Cancer
National Institutes of Health Clinical Center (CC)
Ferumoxytol Enhanced MRI for the Detection of Lymph Node Involvement in Prostate Cancer
National Institutes of Health Clinical Center (CC)
Veliparib in Treating Patients With Malignant Solid Tumors That Do Not Respond to Previous Therapy
National Cancer Institute (NCI)
Using Fiducial Markers to Aid in Prostate Cancer Radiation Treatment
National Institutes of Health Clinical Center (CC)
A Phase I Feasibility Study of an Intraprostatic PSA-Based Vaccine in Men With Prostate Cancer With Local Failure Following Radiotherapy or Cryotherapy or Clinical Progression on Androgen Deprivation Therapy in the Absence of Local Definitive Therapy
National Institutes of Health Clinical Center (CC)
Diindolylmethane in Treating Patients Undergoing Surgery for Stage I or Stage II Prostate Cancer
National Cancer Institute (NCI)
Flavopiridol in Treating Patients With Refractory Cancer
National Cancer Institute (NCI)
Lycopene in Healthy Male Participants
National Cancer Institute (NCI)
Se-Methyl-Seleno-L-Cysteine or Selenomethionine in Preventing Prostate Cancer in Healthy Participants
National Cancer Institute (NCI)
Defined Green Tea Catechins in Treating Patients With Prostate Cancer Undergoing Surgery to Remove the Prostate
National Cancer Institute (NCI)
Combination Chemotherapy in Treating Patients With Metastatic or Unresectable Solid Tumors
National Cancer Institute (NCI)
Combination Chemotherapy in Treating Patients With Advanced Prostate Cancer
National Cancer Institute (NCI)
SU006668 in Treating Patients With Advanced Solid Tumors
National Cancer Institute (NCI)
7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Triple Negative Breast Cancer (Currently Accruing Only Triple-negative Breast Cancer Patients Since 6/8/2007)
National Cancer Institute (NCI)
Monoclonal Antibody Therapy Plus Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy
National Cancer Institute (NCI)
Intensity-Modulated Radiation Therapy in Treating Patients With Prostate Cancer
National Cancer Institute (NCI)
Vaccine Therapy in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy
National Cancer Institute (NCI)
Estramustine, Docetaxel, and Carboplatin in Treating Patients With Prostate Cancer That Has Not Responded to Hormone Therapy
National Cancer Institute (NCI)
AMG-479 in Treating Patients With Advanced Solid Tumors or Non-Hodgkin Lymphoma
National Cancer Institute (NCI)
High-Intensity Focused Ultrasound in Treating Patients With Locally Recurrent Prostate Cancer
National Cancer Institute (NCI)
Ultrasound in Treating Patients With Prostate Cancer Confined to the Prostate
National Cancer Institute (NCI)
Lycopene In Preventing of Prostate Cancer
National Cancer Institute (NCI)
Lycopene in Preventing Prostate Cancer in Healthy Participants
National Cancer Institute (NCI)
Lycopene in Preventing Prostate Cancer in Patients Who Are at High Risk of Developing Prostate Cancer
National Cancer Institute (NCI)
Suberoylanilide Hydroxamic Acid in Treating Patients With Advanced Cancer
National Cancer Institute (NCI)
Liposomal Doxorubicin and Thermal Therapy in Treating Patients With Prostate Cancer
National Cancer Institute (NCI)
Alvespimycin Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors
National Cancer Institute (NCI)
Biological Therapy in Treating Patients With Prostate Cancer
National Cancer Institute (NCI)
Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu
National Cancer Institute (NCI)
Vaccine Therapy in Treating Patients With Metastatic Prostate Cancer
National Cancer Institute (NCI)
Trastuzumab Plus R115777 in Treating Patients With Advanced or Metastatic Cancer
National Cancer Institute (NCI)
Interleukin-12 in Treating Patients With Refractory Advanced-Stage Ovarian Cancer or Abdominal Cancer
National Cancer Institute (NCI)